<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2015.3391</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-3391</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>ZHONG</surname><given-names>FEI</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref>
<xref rid="fn1-ol-0-0-3391" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>YANG</surname><given-names>JING</given-names></name>
<xref rid="af2-ol-0-0-3391" ref-type="aff">2</xref>
<xref rid="fn1-ol-0-0-3391" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>TONG</surname><given-names>ZHU-TING</given-names></name>
<xref rid="af3-ol-0-0-3391" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>CHEN</surname><given-names>LIU-LIU</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>FAN</surname><given-names>LU-LU</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>WANG</surname><given-names>FANG</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>ZHA</surname><given-names>XIA-LI</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>LI</surname><given-names>JUN</given-names></name>
<xref rid="af1-ol-0-0-3391" ref-type="aff">1</xref>
<xref ref-type="corresp" rid="c1-ol-0-0-3391"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-3391"><label>1</label>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China</aff>
<aff id="af2-ol-0-0-3391"><label>2</label>Department of Neurology, Anhui Provincial Hospital, Hefei, Anhui 230001, P.R. China</aff>
<aff id="af3-ol-0-0-3391"><label>3</label>Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-3391"><italic>Correspondence to</italic>: Professor Jun Li, Department of Oncology, The First Affiliated Hospital of Anhui Medical University, 218 Ji Xi Road, Hefei, Anhui 230022, P.R. China, E-mail: <email>18226616729@163.com</email></corresp>
<fn id="fn1-ol-0-0-3391"><label>&#x002A;</label><p>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>09</month>
<year>2015</year></pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>06</month>
<year>2015</year></pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>1416</fpage>
<lpage>1422</lpage>
<history>
<date date-type="received"><day>09</day><month>07</month><year>2014</year></date>
<date date-type="accepted"><day>27</day><month>05</month><year>2015</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhong et al. This is an open access article distributed under the terms of a Creative Commons Attribution License.</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<abstract>
<p>Guggulsterone has recently been reported to demonstrate anti-tumor effects in a variety of cancers. The present study aims to investigate the biological roles and underlying mechanism of the action of guggulsterone in cholangiocarcinoma. The immortalized human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell lines were treated with various concentrations of the <italic>trans</italic> isomer of guggulsterone, Z-guggulsterone. Cellular proliferation was determined using the XTT assay. The apoptotic status of cholangiocarcinoma cells was assessed by Hoechst 33258 staining, DNA fragmentation assay and &#xFB02;ow cytometry. Specific caspase inhibitor was used to explore the role of caspase in guggulsterone-induced apoptosis. A colorimetric assay was performed to measure the alterations of the activities of caspase-3, -8 and -9. Western blot analysis was used to detect the protein expression of survivin, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein and cleaved poly (adenosine diphosphate-ribose) polymerase (PARP). As revealed by the present data, guggulsterone significantly inhibited the growth of the two human cholangiocarcinoma cell lines by inducing cellular apoptosis. In addition, guggulsterone-induced apoptosis of cholangiocarcinoma cells was demonstrated to be partially inhibited by the caspase inhibitors z-VAD-fmk, z-LEHD-fmk and z-IETD-fmk, accompanied by the activation of caspases-3, -8 and -9, accumulation of cleaved PARP and decreased expression of survivin and Bcl-2. In conclusion, the present study demonstrated that guggulsterone was able to suppress the proliferation of cholangiocarcinoma by inducing caspase-dependent apoptosis and downregulating survivin and Bcl-2.</p>
</abstract>
<kwd-group>
<kwd>guggulsterone</kwd>
<kwd>cholangiocarcinoma</kwd>
<kwd>apoptosis</kwd>
<kwd>caspase</kwd>
<kwd>Survivin</kwd>
<kwd>B-cell lymphoma 2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Cholangiocarcinoma is a malignancy that arises from the neoplastic transformation of cholangiocytes, and currently, this disease accounts for between 10 and 15&#x0025; of all hepatobiliary tumors and the incidence is rising globally (<xref rid="b1-ol-0-0-3391" ref-type="bibr">1</xref>,<xref rid="b2-ol-0-0-3391" ref-type="bibr">2</xref>). Despite previous advances in illustrating the molecular characteristics of cholangiocarcinoma, the treatment remains challenging, and there has been no significant change in the overall five-year survival rate of patients over previous decades (<xref rid="b3-ol-0-0-3391" ref-type="bibr">3</xref>,<xref rid="b4-ol-0-0-3391" ref-type="bibr">4</xref>). Therefore, exploration of the molecular events underlying the initiation and progression of cholangiocarcinoma is urgently required.</p>
<p>Apoptosis, also termed programmed cell death, plays an important role in controlling cellular proliferation as part of normal development (<xref rid="b5-ol-0-0-3391" ref-type="bibr">5</xref>). Numerous previous studies have revealed that downregulated apoptotic pathways contribute to chemoresistance in cancer cells, and enhanced apoptosis is a key mechanism by which chemotherapeutic agents exert their antitumor effects (<xref rid="b6-ol-0-0-3391" ref-type="bibr">6</xref>,<xref rid="b7-ol-0-0-3391" ref-type="bibr">7</xref>). Thus, the induction of apoptosis is currently considered to be an index for selecting novel anticancer drugs (<xref rid="b7-ol-0-0-3391" ref-type="bibr">7</xref>,<xref rid="b8-ol-0-0-3391" ref-type="bibr">8</xref>).</p>
<p>Guggulsterone is a polyphenol that is derived from <italic>Commiphora mukul</italic>, a plant native to India. For thousands of years, guggulsterone has been used to treat various human diseases, including in&#xFB02;ammation, arthritis and cardiovascular disease (<xref rid="b9-ol-0-0-3391" ref-type="bibr">9</xref>&#x2013;<xref rid="b11-ol-0-0-3391" ref-type="bibr">11</xref>). The active components of this herbal extract are the <italic>trans</italic> Z- and <italic>cis</italic> E-isomers of guggulsterone (<xref rid="b12-ol-0-0-3391" ref-type="bibr">12</xref>).</p>
<p>Previous studies have reported that guggulsterone possesses anticancer potential due to the anti-proliferative and apoptosis-inducing effects exerted by this agent on a panel of human cancers, including leukemia, breast carcinoma, prostate cancer, colorectal cancer, pancreatic carcinoma and esophageal cancer (<xref rid="b13-ol-0-0-3391" ref-type="bibr">13</xref>&#x2013;<xref rid="b18-ol-0-0-3391" ref-type="bibr">18</xref>).</p>
<p>However, to the best of our knowledge, the effect of guggulsterone on human cholangiocarcinoma remains to be elucidated. In the present study, the effects of guggulsterone on cellular proliferation and apoptosis in cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells were explored, and the underlying mechanism was investigated.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Reagents</title>
<p>Z-guggulsterone (<xref rid="f1-ol-0-0-3391" ref-type="fig">Fig.1</xref>) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The stock solution was prepared in dimethyl sulfoxide (DMSO; Solar Biotechnology, Inc., Shanghai, China) and then diluted with serum-free medium. RPMI-1640 and heat-inactivated fetal calf serum were obtained from Gibco Industries (Tulsa, OK, USA). The XTT proliferation kit and Hoechst 33258 were purchased from Boehringer Ingelheim (Mannheim, Germany). The Caspase Activity Colorimetric Assay kit, pan-caspase inhibitor z-VAD-fmk, capase-8 inhibitor z-IETD-fmk and caspase-9 inhibitor z-LEHD-fmk were purchased from Assay Designs (Ann Arbor, MI, USA). The following primary antibodies were also used: Rabbit anti-cleaved poly (adenosine diphosphate-ribose) polymerase (PARP; cat no. G3411; Promega, Madison, WI, USA); mouse anti-human survivin (cat no. sc-65610; 1:300 dilution; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); mouse anti-human B-cell lymphoma 2 (Bcl-2; cat no. sc-377576; 1:500 dilution; Santa Cruz Biotechnology, Inc.); and goat anti-human Bcl-2-associated X protein (cat no. sc-20287; 1:1,100 dilution; Santa Cruz Biotechnology, Inc.). The rabbit anti-mouse (cat no. sc-358961; 1:1,000 dilution), bovine anti-rabbit (cat no. sc-362290; 1:1,000 dilution) and bovine anti-goat (cat no. sc-362284; 1:1,000 dilution) secondary antibodies were all obtained from Santa Cruz Biotechnology, Inc. The present study was approved by the ethics committee of Anhui Medical University (Hefei, China).</p>
</sec>
<sec>
<title>Cell lines culture</title>
<p>The human immortalized cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell lines were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The cells were routinely cultured in RPMI-1640 supplemented with 10&#x0025; heat-inactivated fetal calf serum, 2 mmol/l L-glutamine and 5 U/ml penicillin (Solar Biotechnology, Inc.)in a humidified incubator with a 5&#x0025; CO<sub>2</sub> atmosphere at 37&#x00B0;C.</p>
</sec>
<sec>
<title>Cell viability assay</title>
<p>The effects of guggulsterone on the viability of Sk-ChA-1 and Mz-ChA-1 cells were determined by the XTT assay. In brief, 1&#x00D7;10<sup>4</sup> cells/well were seeded into a 96-well plate and incubated for 24 h, and these cells were then treated with 0, 20, 40 and 60 &#x00B5;mol/l Z-guggulsterone. Cells treated with only DMSO were used as the control. At the indicated time points, 50 &#x00B5;l of XTT/phenazine methosulfate (PMS) mixture (Solar Biotechnology, Inc.), consisting of 50 &#x00B5;mol/l PMS and 0.1&#x0025; XTT in medium, was added to the cell culture media and incubated continuously for 4 hours. The absorbance at 450 nm was then measured using a Synergy&#x2122; HT multi-mode microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).</p>
</sec>
<sec>
<title>Hoechst 33258 staining</title>
<p>The cholangiocarcinoma cells were seeded into a six-well plate and routinely cultured overnight in RPMI-1640 medium containing 10&#x0025; fetal calf serum. These cells were then treated with 60 &#x00B5;mol/l Z-guggulsterone for 72 h. Subsequently, the cells were fixed with 4&#x0025; formaldehyde for 15 min at room temperature. The cells were then washed twice with 1X phosphate-buffered saline (PBS) and stained with 10 mg/l Hoechst 33258 for 1 h at room temperature. Finally, the alterations in nuclear morphology were observed under fluorescence microscopy (Nikon TE 2000-U; Nikon, Tokyo, Japan).</p>
</sec>
<sec>
<title>DNA fragmentation assay</title>
<p>In total, 1&#x00D7;10<sup>6</sup> cells were harvested and washed once in 1X Ca<sub>2</sub><sup>&#x002B;</sup>- and Mg<sub>2</sub><sup>&#x002B;</sup>-free PBS. The cells were then suspended in 400 &#x00B5;l cell lysis buffer consisting of 10 mM Tris-HCl (pH 7.4; Solar Biotechnology, Inc.), 10 mM EDTA (pH 8.0) and 0.5&#x0025; Triton X-100 (Solar Biotechnology, Inc.). The suspension was incubated at 4&#x00B0;C for 15 min. Following centrifugation of the cell lysates at 15,000 &#x00D7; g for 20 min, the supernatants were collected and incubated with 40 &#x00B5;g/ml proteinase K and 40 &#x00B5;g/ml RNase A (SBS Genetech Co., Beijing, China) at 37&#x00B0;C for 3 h. The lysate was isolated using 0.5 M NaCl and 50&#x0025; 2-propanol and incubated at &#x2212;20&#x00B0;C overnight. Subsequent to centrifugation at 15000 &#x00D7; g for 20 min, the pellets were suspended in Tris-EDTA buffer consisting of 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA (pH 8.0). The genomic DNA was separated using a 2&#x0025; agarose gel and stained with 0.1 &#x00B5;g/ml ethidium bromide (<xref rid="b19-ol-0-0-3391" ref-type="bibr">19</xref>).</p>
</sec>
<sec>
<title>Flow cytometry</title>
<p>Flow cytometry analysis was performed as previously described (<xref rid="b18-ol-0-0-3391" ref-type="bibr">18</xref>). In brief, the cells treated with Z-guggulsterone or DMSO were harvested and &#xFB01;xed with 75&#x0025; ethanol at &#x2212;20&#x00B0;C. Subsequent to washing twice with cold PBS, the fixed cells were then suspended in 100 &#x00B5;l RNase A solution (1 mg/ml) and incubated at 37&#x00B0;C for 1 h. Next, 400 &#x00B5;l propidium iodide solution (50 &#x00B5;g/ml) was added to the cells, and the cells were subsequently incubated for 30 min in the dark. Following incubation, the apoptotic status of these cells was measured using a FACScan flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA). The data were further analyzed using CellQuest Software (Becton-Dickinson). In the caspase inhibitor assay, the cells were treated with 60 &#x00B5;mol/l Z-guggulsterone for 72 h, with or without 2-h pre-treatment in 100 &#x00B5;M of the specific caspase inhibitors. Cellular apoptosis was then measured as aforementioned.</p>
</sec>
<sec>
<title>Caspase activity assay</title>
<p>The activity of caspases-3, -8 and -9 was determined using the colorimetric assay kit, according to the manufacturer&#x0027;s instructions. In brief, the cells were lysed in buffer containing 5 mM DTT (Solar Biotechnology, Inc.), 10 &#x00B5;g/ml aprotinin (Santa Cruz Biotechnology, Inc.), 20 mM EDTA (Solar Biotechnology, Inc.), 50 mM HEPES (SBS Genetech Co.), 0.2&#x0025; Triton X-100 (Santa Cruz Biotechnology, Inc.), 150 mM NaCl and 1 mM phenylmethylsulfonyl fluoride (Santa Cruz Biotechnology, Inc.) at 4&#x00B0;C for 10 min. Following centrifugation at 10,000 &#x00D7; g for 10 min at 4&#x00B0;C, the supernatant was collected and the protein concentration was measured. Subsequently, 100 &#x00B5;g protein was incubated with 0.2 mM DEVD-pNA, IETD-pNAu or LEHD-pNA (Santa Cruz Biotechnology, Inc.), which are substrates of caspases-3, -8 and -9, respectively. The caspase activity was determined from the absorbance at 405 nm using the microplate reader.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Total protein was extracted using the RIPA lysis buffer containing protease inhibitors. Equal amounts of protein (20&#x2013;50 &#x00B5;g) were then loaded and separated by 12&#x0025; SDS-PAGE and transferred onto the nitrocellulose membranes. For the blocking procedure, the membranes were incubated in 5&#x0025; non-fat milk for 1 h. Appropriate primary antibodies were added to the membrane and the membrane was then incubated at room temperature for 2 h. Next, the membranes were incubated with the appropriate secondary antibodies for 2 h at room temperature. The specific protein bands were then developed using a commercial enhanced P1701 chemiluminescence kit (Applygen Technologies Inc., Beijing, China). The staining density was measured using the GS-710 Imaging Densitometer, which was obtained from Bio-Rad Laboratories (Hercules, CA, USA).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were performed in triplicate and repeated at least three times. The data were expressed as the mean &#x00B1; standard deviation. Student&#x0027;s <italic>t</italic>-test was used to determine the significance of the differences between groups. SPSS software (version 15.0; SPSS, Inc., Chicago, IL, USA) was used to perform all statistical analyses and P&#x003C;0.01 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Z-guggulsterone suppressed the proliferation of cholangiocarcinoma cells by enhancing cellular apoptosis</title>
<p>To investigate the cytotoxicity of guggulsterone on cholangiocarcinoma cells, the Sk-ChA-1 and Mz-ChA-1 cells were incubated with Z-guggulsterone for 24, 48 and 72 h. As demonstrated by the present data, treatment with Z-guggulsterone resulted in significant growth suppression of the two cell lines in a dose- and time-dependent manner (P&#x003C;0.001 vs. control; <xref rid="f2-ol-0-0-3391" ref-type="fig">Fig. 2</xref>). In addition, the Mz-ChA-1 and Sk-ChA-1 cells were sensitive to treatment with Z-guggulsterone. In the group of cells treated with 60 &#x00B5;mol/l Z-guggulsterone for 72 h, the cell viability of Sk-ChA-1 and Mz-ChA-1 cells was 18.78 and 26.98&#x0025;, respectively.</p>
<p>Hoechst 33258 staining and DNA fragmentation analysis were then performed to investigate whether cytotoxicity induced by guggulsterone resulted from cellular apoptosis. According to the results of Hoechst staining, 72-h treatment with Z-guggulsterone led to notable morphological alterations, such as chromatin condensation and nuclear fragmentation, which were observed in each of the two cholangiocarcinoma cell lines (<xref rid="f3-ol-0-0-3391" ref-type="fig">Fig. 3A</xref>). In the agarose gel electrophoresis, a DNA fragment ladder was detected subsequent to 48-h treatment with guggulsterone, which was more notable subsequent to 72-h treatment in each of the two cell lines (<xref rid="f3-ol-0-0-3391" ref-type="fig">Fig. 3B</xref>). These findings indicated that that guggulsterone may lead to the death of cholangiocarcinoma cells by inducing cellular apoptosis. In addition, flow cytometry was performed to quantify the apoptosis induced by guggulsterone. As revealed in <xref rid="f3-ol-0-0-3391" ref-type="fig">Fig. 3C</xref>, there was a significant dose- and time-dependent increase in the proportion of Sk-ChA-1 and Mz-ChA-1 cells in the sub-G1 phase subsequent to treatment with &#x2265;20 &#x00B5;mol/l Z-guggulsterone (P&#x003C;0.001 vs. control). In addition to the increase of cell growth suppression, cellular apoptosis was also upregulated gradually and the sub-G1 population of the two cells was &#x003E;50&#x0025; when the cells were treated with 60 &#x00B5;mol/l Z-guggulsterone for 72 h.</p>
</sec>
<sec>
<title>Involvement of caspases in apoptosis induced by Z-guggulsterone</title>
<p>Considering that caspases play critical roles in cellular apoptosis, the effects of caspase inhibition on Z-guggulsterone-induced apoptosis were then explored. Three caspase inhibitors, consisting of pan-caspase, caspase-8 and caspase-9 inhibitors, were used in the present study. As shown in <xref rid="f4-ol-0-0-3391" ref-type="fig">Fig. 4A</xref>, these inhibitors significantly impaired the apoptosis induced by Z-guggulsterone in Sk-ChA-1 (P&#x003C;0.01) and Mz-ChA-1 (P&#x003C;0.001) cells, compared with the cells treated with Z-guggulsterone.</p>
<p>The activity of caspases-3, -8 and -9 following treatment with 60 &#x00B5;mol/l Z-guggulsterone was then assessed using colorimetric assay kits. In the Sk-ChA-1 and Mz-ChA-1 cell lines, the highest activity of caspases-8 and -9 was detected at subsequent to treatment for 48 h, which was followed by a further enhancement of caspase-3 activity subsequent to 72 h of treatment (<xref rid="f4-ol-0-0-3391" ref-type="fig">Fig. 4B</xref>). In addition, the level of cleaved PARP, a hallmark of apoptosis, significantly increased following treatment with 60 &#x00B5;mol/l Z-guggulsterone in a time-dependent manner (<xref rid="f4-ol-0-0-3391" ref-type="fig">Fig. 4C</xref>). Overall, the present findings indicated that guggulsterone may induce cytotoxicity in cholangiocarcinoma cells through caspase-dependent apoptosis.</p>
</sec>
<sec>
<title>Guggulsterone regulates apoptosis-associated genes</title>
<p>According to the results of western blot analysis, the protein levels of survivin and Bcl-2 were markedly downregulated in a time-dependent manner, while the expression of Bax remained constant (<xref rid="f5-ol-0-0-3391" ref-type="fig">Fig. 5</xref>), indicating the important roles of survivin and Bcl-2 during the apoptosis induced by guggulsterone.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>At present, anticancer drugs extracted from plants, such as Adriamycin (<xref rid="b20-ol-0-0-3391" ref-type="bibr">20</xref>), paclitaxel (<xref rid="b21-ol-0-0-3391" ref-type="bibr">21</xref>) and etoposide (<xref rid="b22-ol-0-0-3391" ref-type="bibr">22</xref>), are widely used in clinical settings. The identification of novel anti-cancer agents from natural plants is becoming a well-known strategy for studies (<xref rid="b23-ol-0-0-3391" ref-type="bibr">23</xref>).</p>
<p>In the present study, it was demonstrated that guggulsterone was able to inhibit the proliferation of the cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell lines, indicating that guggulsterone may be a good candidate for additional investigation as a chemotherapeutic agent for cholangiocarcinoma.</p>
<p>A panel of experiments was then performed to explore the underlying mechanisms of the effect of guggulsterone. Hoechst 33258 staining revealed that treatment with guggulsterone resulted in notable morphological indications of apoptosis, including the condensation of chromatin and nuclear fragmentation in cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells. In addition, typical DNA fragmentation, a hallmark of apoptosis, was also observed subsequent to the cells being treated with 60 &#x00B5;mol/l Z-guggulsterone for 48 and 72 h. Flow cytometry revealed that Z-guggulsterone induced apoptosis in cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells in a time- and dose-dependent manner. Consistently, the present findings were supported by previous studies that identified similar effects of guggulsterone in other types of cancer cells (<xref rid="b13-ol-0-0-3391" ref-type="bibr">13</xref>&#x2013;<xref rid="b16-ol-0-0-3391" ref-type="bibr">16</xref>).</p>
<p>As previously reported, there are two major signaling pathways involved in apoptosis, the extrinsic death receptor pathway and intrinsic mitochondrial pathway (<xref rid="b24-ol-0-0-3391" ref-type="bibr">24</xref>&#x2013;<xref rid="b27-ol-0-0-3391" ref-type="bibr">27</xref>). In the extrinsic pathway, caspase-8 is first activated by the death-inducing signaling complex. The active form of caspase-8 then activates downstream executioner caspases, including caspase-3, and also cleaves BH3 interacting domain death agonist (Bid) into truncated Bid, which eventually leads to the activation of the intrinsic pathway (<xref rid="b28-ol-0-0-3391" ref-type="bibr">28</xref>). In the intrinsic pathway, several apoptogenic molecules, including cytochrome <italic>c</italic> and apoptosis-inducing factor, are released into the cytosol following the mitochondrial membrane permeability transition (<xref rid="b25-ol-0-0-3391" ref-type="bibr">25</xref>). Cytochrome <italic>c</italic> then interacts with apoptotic protease-activating factor 1 and pro-caspase-9, and subsequently activates caspase-9 (<xref rid="b23-ol-0-0-3391" ref-type="bibr">23</xref>,<xref rid="b24-ol-0-0-3391" ref-type="bibr">24</xref>). The active caspase-9 activates proteins, including pro-caspase-3 and cleaved PARP, which initiates a cascade that finally leads to cellular apoptosis (<xref rid="b27-ol-0-0-3391" ref-type="bibr">27</xref>). In addition, there are also several other caspase-independent pathways (<xref rid="b29-ol-0-0-3391" ref-type="bibr">29</xref>). For example, apoptosis-inducing factor may translocate from the mitochondrial intermembrane to the nucleus and result in chromatin condensation and large-scale DNA fragmentation, leading to apoptotic cell death (<xref rid="b30-ol-0-0-3391" ref-type="bibr">30</xref>).</p>
<p>In addition, pre-treatment with the caspase inhibitors z-VAD-fmk, z-LEHD-fmk and z-IETD-fmk effectively impaired guggulsterone-induced apoptosis, indicating that caspase cascades play critical roles during the induction of apoptosis caused by guggulsterone. The colorimetric assay revealed that guggulsterone activated caspases-8, -9 and -3. As the main substrate of caspases, the alteration in the expression of cleaved PARP also supports this conclusion. Consistent with the present results, several other studies have reported that caspase-dependent apoptosis induced by guggulsterone also occurred in prostate and colon cancer cells (<xref rid="b13-ol-0-0-3391" ref-type="bibr">13</xref>,<xref rid="b16-ol-0-0-3391" ref-type="bibr">16</xref>). Additional studies investigating the possibility that guggulsterone triggers apoptosis through caspase-independent pathways are required in the future, as the caspase inhibitors used in the present study did not completely abolish guggulsterone-induced apoptosis.</p>
<p>Survivin is a member of the inhibitor of apoptosis protein family and is usually overexpressed in human cancers (<xref rid="b31-ol-0-0-3391" ref-type="bibr">31</xref>). It has been found that cancer cells demonstrating overexpression of survivin are resistant to numerous apoptotic stimuli (<xref rid="b32-ol-0-0-3391" ref-type="bibr">32</xref>). By contrast, the downregulation of survivin causes spontaneous apoptosis or sensitizes cancer cells to these apoptotic stimuli (<xref rid="b32-ol-0-0-3391" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-ol-0-0-3391" ref-type="bibr">34</xref>). It has previously been reported that survivin is overexpressed in the majority of cholangiocarcinoma cells, which was closely associated with poor outcomes, indicating that survivin may be a promising target for the treatment of cholangiocarcinoma (<xref rid="b35-ol-0-0-3391" ref-type="bibr">35</xref>&#x2013;<xref rid="b37-ol-0-0-3391" ref-type="bibr">37</xref>).</p>
<p>The Bcl-2 family, which consists of &#x007E;20 homologues of apoptosis-inhibiting and apoptosis-promoting Bcl-2 proteins, plays key regulatory roles in mitochondria-mediated apoptosis (<xref rid="b38-ol-0-0-3391" ref-type="bibr">38</xref>). Bcl-2 and Bax are major apoptosis-inhibiting and -promoting proteins, respectively (<xref rid="b39-ol-0-0-3391" ref-type="bibr">39</xref>). It has previously been revealed that invalid therapeutic outcomes are mostly associated with the overexpression of apoptosis-inhibiting proteins, particularly Bcl-2, in numerous types of human cancer (<xref rid="b40-ol-0-0-3391" ref-type="bibr">40</xref>). By contrast, Bax has been revealed to constitute a requisite gateway to the mitochondria-dependent pathway of apoptosis (<xref rid="b41-ol-0-0-3391" ref-type="bibr">41</xref>). Therefore, upregulating the level of Bax may also improve the sensitivities to anti-cancer agents in these cancer cells (<xref rid="b42-ol-0-0-3391" ref-type="bibr">42</xref>). In addition, Bcl-2 and Bax may dimerize with each other and mutually neutralize their biological functions, resulting in the initiation of apoptosis (<xref rid="b39-ol-0-0-3391" ref-type="bibr">39</xref>). Thus, the Bcl-2/Bax ratio is an important index for the determination of cellular susceptibility to apoptosis (<xref rid="b43-ol-0-0-3391" ref-type="bibr">43</xref>).</p>
<p>The present study revealed that guggulsterone-induced apoptosis is accompanied by a reduction in the expression of survivin and Bcl-2. Despite survivin and Bcl-2 each acting as apoptosis inhibitors, these proteins execute biological functions through various pathways that regulate cellular apoptosis (<xref rid="b44-ol-0-0-3391" ref-type="bibr">44</xref>). Survivin may directly interact with and suppress the terminal effector cell-death proteases, such as caspase-3 and caspase-7 (<xref rid="b40-ol-0-0-3391" ref-type="bibr">40</xref>), while Bcl-2 mainly prevents the release of cytochrome <italic>c</italic> and then blocks the progression of apoptosis (<xref rid="b34-ol-0-0-3391" ref-type="bibr">34</xref>). The present study identified that survivin and Bcl-2 were concurrently downregulated by guggulsterone, which was consistent with the findings of previous studies (<xref rid="b41-ol-0-0-3391" ref-type="bibr">41</xref>,<xref rid="b42-ol-0-0-3391" ref-type="bibr">42</xref>).</p>
<p>In summary, the present study demonstrated that guggulsterone suppressed tumor proliferation by inducing cellular apoptosis in human cholangiocarcinoma cells. The current study also revealed that the apoptosis induced by guggulsterone was caspase-dependent and accompanied by the downregulation of survivin and Bcl-2. These findings indicate the therapeutic potential of guggulsterone in treating cholangiocarcinoma.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the Scientific Research Foundation of Anhui Medical University (grant no., 2012xkj049), Youth Talents Plan of the First Affiliated Hospital of Anhui Medical University (grant no., 2010KJ01) and Natural Science Foundation of Higher Education of Anhui Province (grant no., KJ2012A163).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-3391"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaridis</surname><given-names>KN</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name></person-group><article-title>Cholangiocarcinoma</article-title><source>Gastroenterology</source><volume>128</volume><fpage>1655</fpage><lpage>1667</lpage><year>2005</year><pub-id pub-id-type="doi">10.1053/j.gastro.2005.03.040</pub-id><pub-id pub-id-type="pmid">15887157</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-3391"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>H</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Aithal</surname><given-names>GP</given-names></name></person-group><article-title>Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971&#x2013;2001</article-title><source>Br J Cancer</source><volume>94</volume><fpage>1751</fpage><lpage>1758</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6603127</pub-id><pub-id pub-id-type="pmid">16736026</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-3391"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CD</given-names></name><name><surname>Pinson</surname><given-names>CW</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><name><surname>Chari</surname><given-names>RS</given-names></name></person-group><article-title>Diagnosis and treatment of cholangiocarcinoma</article-title><source>Oncologist</source><volume>9</volume><fpage>43</fpage><lpage>57</lpage><year>2004</year><pub-id pub-id-type="doi">10.1634/theoncologist.9-1-43</pub-id><pub-id pub-id-type="pmid">14755014</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-3391"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirica</surname><given-names>AE</given-names></name></person-group><article-title>Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy</article-title><source>Hepatology</source><volume>41</volume><fpage>5</fpage><lpage>15</lpage><year>2005</year><pub-id pub-id-type="doi">10.1002/hep.20537</pub-id><pub-id pub-id-type="pmid">15690474</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-3391"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Gorman</surname><given-names>AM</given-names></name><name><surname>Hori</surname><given-names>O</given-names></name><name><surname>Samali</surname><given-names>A</given-names></name></person-group><article-title>Cellular stress responses: Cell survival and cell death</article-title><source>Int J Cell Biol</source><volume>2010</volume><fpage>214074</fpage><year>2010</year><pub-id pub-id-type="doi">10.1155/2010/214074</pub-id><pub-id pub-id-type="pmid">20182529</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-3391"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabregat</surname><given-names>I</given-names></name><name><surname>Roncero</surname><given-names>C</given-names></name><name><surname>Fern&#x00E1;ndez</surname><given-names>M</given-names></name></person-group><article-title>Survival and apoptosis: A dysregulated balance in liver cancer</article-title><source>Liver Int</source><volume>27</volume><fpage>155</fpage><lpage>162</lpage><year>2007</year><pub-id pub-id-type="doi">10.1111/j.1478-3231.2006.01409.x</pub-id><pub-id pub-id-type="pmid">17311609</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-3391"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>CG</given-names></name><name><surname>Epping</surname><given-names>M</given-names></name><name><surname>Kruyt</surname><given-names>FA</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name></person-group><article-title>Apoptosis: Target of cancer therapy</article-title><source>Clin Cancer Res</source><volume>8</volume><fpage>2024</fpage><lpage>2034</lpage><year>2002</year><pub-id pub-id-type="pmid">12114400</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-3391"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ND</given-names></name><name><surname>Im</surname><given-names>E</given-names></name><name><surname>Yoo</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name></person-group><article-title>Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids</article-title><source>Curr Cancer Drug Targets</source><volume>6</volume><fpage>681</fpage><lpage>689</lpage><year>2006</year><pub-id pub-id-type="doi">10.2174/156800906779010236</pub-id><pub-id pub-id-type="pmid">17168673</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-3391"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gujral</surname><given-names>ML</given-names></name><name><surname>Sareen</surname><given-names>K</given-names></name><name><surname>Tangri</surname><given-names>KK</given-names></name><name><surname>Amma</surname><given-names>MK</given-names></name><name><surname>Roy</surname><given-names>AK</given-names></name></person-group><article-title>Antiarthritic and anti-in&#xFB02;ammatory activity of gum guggul (<italic>Balsamodendron mukul</italic> Hook)</article-title><source>Indian J Physiol Pharmacol</source><volume>4</volume><fpage>267</fpage><lpage>273</lpage><year>1960</year><pub-id pub-id-type="pmid">13709695</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-3391"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>JN</given-names></name><name><surname>Sharma</surname><given-names>JN</given-names></name></person-group><article-title>Comparison of the anti-in&#xFB02;ammatory activity of <italic>Commiphora mukul</italic> (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant</article-title><source>Arzneimittelforschung</source><volume>27</volume><fpage>1455</fpage><lpage>1457</lpage><year>1977</year><pub-id pub-id-type="pmid">578471</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-3391"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urizar</surname><given-names>NL</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><article-title>GUGULIPID: A natural cholesterol-lowering agent</article-title><source>Annu Rev Nutr</source><volume>23</volume><fpage>303</fpage><lpage>313</lpage><year>2003</year><pub-id pub-id-type="doi">10.1146/annurev.nutr.23.011702.073102</pub-id><pub-id pub-id-type="pmid">12626688</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-3391"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urizar</surname><given-names>NL</given-names></name><name><surname>Liverman</surname><given-names>AB</given-names></name><name><surname>Dodds</surname><given-names>DT</given-names></name><name><surname>Silva</surname><given-names>FV</given-names></name><name><surname>Ordentlich</surname><given-names>P</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><article-title>A natural product that lowers cholesterol as an antagonist ligand for FXR</article-title><source>Science</source><volume>296</volume><fpage>1703</fpage><lpage>1706</lpage><year>2002</year><pub-id pub-id-type="doi">10.1126/science.1072891</pub-id><pub-id pub-id-type="pmid">11988537</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-3391"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SV</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Hahm</surname><given-names>ER</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name></person-group><article-title>Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH<sub>2</sub> -terminal kinase</article-title><source>Cancer Res</source><volume>67</volume><fpage>7439</fpage><lpage>7449</lpage><year>2007</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0120</pub-id><pub-id pub-id-type="pmid">17671214</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-3391"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shishodia</surname><given-names>S</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Ahn</surname><given-names>KS</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products</article-title><source>Biochem Pharmacol</source><volume>74</volume><fpage>118</fpage><lpage>130</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.bcp.2007.03.026</pub-id><pub-id pub-id-type="pmid">17475222</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-3391"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samudio</surname><given-names>I</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name><name><surname>McQueen</surname><given-names>T</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name></person-group><article-title>Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: Identification of isomer-specific antileukemic activities of the pregnadienedione structure</article-title><source>Mol Cancer Ther</source><volume>4</volume><fpage>1982</fpage><lpage>1992</lpage><year>2005</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0247</pub-id><pub-id pub-id-type="pmid">16373713</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-3391"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>MJ</given-names></name><name><surname>Cheon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>ES</given-names></name><name><surname>Kim</surname><given-names>TI</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name></person-group><article-title>Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts</article-title><source>Cancer Letters</source><volume>279</volume><fpage>93</fpage><lpage>100</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.canlet.2009.01.026</pub-id><pub-id pub-id-type="pmid">19232820</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-3391"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macha</surname><given-names>MA</given-names></name><name><surname>Rachagani</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Pai</surname><given-names>P</given-names></name><name><surname>Ponnusamy</surname><given-names>MP</given-names></name><name><surname>Batra</surname><given-names>SK</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name></person-group><article-title>Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling</article-title><source>Cancer Lett</source><volume>341</volume><fpage>166</fpage><lpage>177</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.canlet.2013.07.037</pub-id><pub-id pub-id-type="pmid">23920124</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-3391"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Hoque</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Inhibition of farnesoid X receptor controls esophageal cancer cell growth <italic>in vitro</italic> and in nude mouse xenografts</article-title><source>Cancer</source><volume>119</volume><fpage>1321</fpage><lpage>1329</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/cncr.27910</pub-id><pub-id pub-id-type="pmid">23280144</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-3391"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Lorenz</surname><given-names>HM</given-names></name><name><surname>Voll</surname><given-names>R</given-names></name><name><surname>Gr&#x00FC;nke</surname><given-names>M</given-names></name><name><surname>Woith</surname><given-names>W</given-names></name><name><surname>Kalden</surname><given-names>JR</given-names></name></person-group><article-title>A rapid and simple method for the isolation of apoptotic DNA fragments</article-title><source>Nucleic Acids Res</source><volume>22</volume><fpage>5506</fpage><lpage>5507</lpage><year>1994</year><pub-id pub-id-type="doi">10.1093/nar/22.24.5506</pub-id><pub-id pub-id-type="pmid">7816645</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-3391"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanjeekal</surname><given-names>S</given-names></name><name><surname>Chambers</surname><given-names>A</given-names></name><name><surname>Fung</surname><given-names>MF</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name></person-group><article-title>Systemic therapy for advanced uterine sarcoma: A systematic review of the literature</article-title><source>Gynecol Oncol</source><volume>97</volume><fpage>624</fpage><lpage>637</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2005.01.041</pub-id><pub-id pub-id-type="pmid">15863170</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-3391"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiseman</surname><given-names>LR</given-names></name><name><surname>Spencer</surname><given-names>CM</given-names></name></person-group><article-title>Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers</article-title><source>Drugs Aging</source><volume>12</volume><fpage>305</fpage><lpage>334</lpage><year>1998</year><pub-id pub-id-type="doi">10.2165/00002512-199812040-00005</pub-id><pub-id pub-id-type="pmid">9571394</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-3391"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>Z</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name></person-group><article-title>A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer</article-title><source>J Thorac Oncol</source><volume>5</volume><fpage>867</fpage><lpage>873</lpage><year>2010</year><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181d95c87</pub-id><pub-id pub-id-type="pmid">20521354</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-3391"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karikas</surname><given-names>GA</given-names></name></person-group><article-title>Anticancer and chemopreventing natural products: Some biochemical and therapeutic aspects</article-title><source>J BUON</source><volume>15</volume><fpage>627</fpage><lpage>638</lpage><year>2010</year><pub-id pub-id-type="pmid">21229622</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-3391"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><article-title>Apoptosis-regulating proteins as targets for drug discovery</article-title><source>Trends Mol Med</source><volume>7</volume><fpage>314</fpage><lpage>319</lpage><year>2001</year><pub-id pub-id-type="doi">10.1016/S1471-4914(01)02026-3</pub-id><pub-id pub-id-type="pmid">11425640</pub-id></element-citation></ref>
<ref id="b25-ol-0-0-3391"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desagher</surname><given-names>S</given-names></name><name><surname>Martinou</surname><given-names>JC</given-names></name></person-group><article-title>Mitochondria as the central control point of apoptosis</article-title><source>Trends Cell Biol</source><volume>10</volume><fpage>369</fpage><lpage>377</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0962-8924(00)01803-1</pub-id><pub-id pub-id-type="pmid">10932094</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-3391"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Loo</surname><given-names>G</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>Van Gurp</surname><given-names>M</given-names></name><name><surname>MacFarlane</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group><article-title>The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet</article-title><source>Cell Death Differ</source><volume>9</volume><fpage>1031</fpage><lpage>1042</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/sj.cdd.4401088</pub-id><pub-id pub-id-type="pmid">12232790</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-3391"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornberry</surname><given-names>NA</given-names></name><name><surname>Lazebnik</surname><given-names>Y</given-names></name></person-group><article-title>Caspases: Enemies within</article-title><source>Science</source><volume>281</volume><fpage>1312</fpage><lpage>1316</lpage><year>1998</year><pub-id pub-id-type="doi">10.1126/science.281.5381.1312</pub-id><pub-id pub-id-type="pmid">9721091</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-3391"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name></person-group><article-title>Targeting extrinsic apoptosis in cancer: Challenges and opportunities</article-title><source>Semin Cell Dev Biol</source><volume>39</volume><fpage>20</fpage><lpage>25</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.semcdb.2015.01.006</pub-id><pub-id pub-id-type="pmid">25617598</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-3391"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name></person-group><article-title>Caspase-independent apoptosis in yeast</article-title><source>Biochim Biophys Acta</source><volume>1783</volume><fpage>1311</fpage><lpage>1319</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.02.018</pub-id><pub-id pub-id-type="pmid">18358844</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-3391"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susin</surname><given-names>SA</given-names></name><name><surname>Lorenzo</surname><given-names>HK</given-names></name><name><surname>Zamzami</surname><given-names>N</given-names></name><name><surname>Marzo</surname><given-names>I</given-names></name><name><surname>Snow</surname><given-names>BE</given-names></name><name><surname>Brothers</surname><given-names>GM</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Jacotot</surname><given-names>E</given-names></name><name><surname>Costantini</surname><given-names>P</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular characterization of mitochondrial apoptosis-inducing factor</article-title><source>Nature</source><volume>397</volume><fpage>441</fpage><lpage>446</lpage><year>1999</year><pub-id pub-id-type="doi">10.1038/17135</pub-id><pub-id pub-id-type="pmid">9989411</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-3391"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Survivin study: What is the next wave?</article-title><source>J Cell Physiol</source><volume>197</volume><fpage>8</fpage><lpage>29</lpage><year>2003</year><pub-id pub-id-type="doi">10.1002/jcp.10327</pub-id><pub-id pub-id-type="pmid">12942537</pub-id></element-citation></ref>
<ref id="b32-ol-0-0-3391"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ambrosini</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>EY</given-names></name><name><surname>Plescia</surname><given-names>J</given-names></name><name><surname>Tognin</surname><given-names>S</given-names></name><name><surname>Marchisio</surname><given-names>PC</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Control of apoptosis and mitotic spindle checkpoint by survivin</article-title><source>Nature</source><volume>396</volume><fpage>580</fpage><lpage>584</lpage><year>1998</year><pub-id pub-id-type="doi">10.1038/25141</pub-id><pub-id pub-id-type="pmid">9859993</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-3391"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>A</given-names></name><name><surname>McGuirk</surname><given-names>M</given-names></name><name><surname>Hockenberry</surname><given-names>TN</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Ashar</surname><given-names>H</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kirschmeier</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway</article-title><source>Oncogene</source><volume>21</volume><fpage>2613</fpage><lpage>2622</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/sj.onc.1205353</pub-id><pub-id pub-id-type="pmid">11965534</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-3391"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltrami</surname><given-names>E</given-names></name><name><surname>Plescia</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>JC</given-names></name><name><surname>Duckett</surname><given-names>CS</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis</article-title><source>J Biol Chem</source><volume>279</volume><fpage>2077</fpage><lpage>2084</lpage><year>2004</year><pub-id pub-id-type="doi">10.1074/jbc.M309479200</pub-id><pub-id pub-id-type="pmid">14581472</pub-id></element-citation></ref>
<ref id="b35-ol-0-0-3391"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>ZR</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YB</given-names></name><name><surname>Qin</surname><given-names>RY</given-names></name></person-group><article-title>Survivin expression induced by doxorubicin in cholangiocarcinoma</article-title><source>World J Gastroenterol</source><volume>10</volume><fpage>415</fpage><lpage>418</lpage><year>2004</year><pub-id pub-id-type="pmid">14760769</pub-id></element-citation></ref>
<ref id="b36-ol-0-0-3391"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javle</surname><given-names>MM</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>LeVea</surname><given-names>CM</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Kuvshinoff</surname><given-names>BW</given-names></name><name><surname>Gibbs</surname><given-names>JF</given-names></name></person-group><article-title>Nuclear survivin expression predicts poor outcome in cholangiocarcinoma</article-title><source>Hepatogastroenterol</source><volume>51</volume><fpage>1653</fpage><lpage>1657</lpage><year>2004</year></element-citation></ref>
<ref id="b37-ol-0-0-3391"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obama</surname><given-names>K</given-names></name><name><surname>Ura</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>A</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name></person-group><article-title>Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma</article-title><source>Hepatology</source><volume>41</volume><fpage>1339</fpage><lpage>1348</lpage><year>2005</year><pub-id pub-id-type="doi">10.1002/hep.20718</pub-id><pub-id pub-id-type="pmid">15880566</pub-id></element-citation></ref>
<ref id="b38-ol-0-0-3391"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonsson</surname><given-names>B</given-names></name></person-group><article-title>Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways</article-title><source>Mol Cell Biochem</source><volume>256&#x2013;257</volume><fpage>141</fpage><lpage>155</lpage><year>2004</year><pub-id pub-id-type="doi">10.1023/B:MCBI.0000009865.70898.36</pub-id></element-citation></ref>
<ref id="b39-ol-0-0-3391"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>Pde S</given-names></name><name><surname>Ornellas</surname><given-names>AA</given-names></name><name><surname>Campos</surname><given-names>MM</given-names></name><name><surname>Scheiner</surname><given-names>MA</given-names></name><name><surname>Fiedler</surname><given-names>W</given-names></name><name><surname>Alves</surname><given-names>G</given-names></name></person-group><article-title>Bax and bcl-2 imbalance and HPB infection in penile tumors and adjacent tissues</article-title><source>Prog Urol</source><volume>14</volume><fpage>353</fpage><lpage>359</lpage><year>2004</year><comment>(In French)</comment><pub-id pub-id-type="pmid">15373177</pub-id></element-citation></ref>
<ref id="b40-ol-0-0-3391"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><article-title>Double identity for proteins of the Bcl-2 family</article-title><source>Nature</source><volume>387</volume><fpage>773</fpage><lpage>776</lpage><year>1997</year><pub-id pub-id-type="doi">10.1038/42867</pub-id><pub-id pub-id-type="pmid">9194558</pub-id></element-citation></ref>
<ref id="b41-ol-0-0-3391"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>MC</given-names></name><name><surname>Zong</surname><given-names>WX</given-names></name><name><surname>Cheng</surname><given-names>EH</given-names></name><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>Panoutsakopoulou</surname><given-names>V</given-names></name><name><surname>Ross</surname><given-names>AJ</given-names></name><name><surname>MacGregor</surname><given-names>GR</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Korsmeyer</surname><given-names>SJ</given-names></name></person-group><article-title>Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death</article-title><source>Science</source><volume>292</volume><fpage>727</fpage><lpage>730</lpage><year>2001</year><pub-id pub-id-type="doi">10.1126/science.1059108</pub-id><pub-id pub-id-type="pmid">11326099</pub-id></element-citation></ref>
<ref id="b42-ol-0-0-3391"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>LJ</given-names></name><name><surname>Tashiro</surname><given-names>S</given-names></name><name><surname>Onodera</surname><given-names>S</given-names></name><name><surname>Ikejima</surname><given-names>T</given-names></name></person-group><article-title>Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway</article-title><source>Acta Pharmacol Sin</source><volume>25</volume><fpage>691</fpage><lpage>698</lpage><year>2004</year><pub-id pub-id-type="pmid">15132839</pub-id></element-citation></ref>
<ref id="b43-ol-0-0-3391"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manion</surname><given-names>MK</given-names></name><name><surname>Hockenbery</surname><given-names>DM</given-names></name></person-group><article-title>Targeting BCL-2-related proteins in cancer therapy</article-title><source>Cancer Biol Ther</source><volume>2</volume><issue>(Sul 1)</issue><fpage>S105</fpage><lpage>S114</lpage><year>2003</year><pub-id pub-id-type="pmid">14508087</pub-id></element-citation></ref>
<ref id="b44-ol-0-0-3391"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanwar</surname><given-names>JR</given-names></name><name><surname>Kamalapuram</surname><given-names>SK</given-names></name><name><surname>Kanwar</surname><given-names>RK</given-names></name></person-group><article-title>Targeting survivin in cancer: The cell-signalling perspective</article-title><source>Drug Discov Today</source><volume>16</volume><fpage>485</fpage><lpage>494</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.drudis.2011.04.001</pub-id><pub-id pub-id-type="pmid">21511051</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-3391" position="float">
<label>Figure 1.</label>
<caption><p>Structure of z-guggulsterone.</p></caption>
<graphic xlink:href="ol-10-03-1416-g00.jpg"/>
</fig>
<fig id="f2-ol-0-0-3391" position="float">
<label>Figure 2.</label>
<caption><p>Cell viability subsequent to treatment with guggulsterone. Following treatment of the Sk-ChA-1 and Mz-ChA-1 cells with various concentrations of Z-guggulsterone for 24, 48 and 72 h, the number of metabolically active cells was determined using a XTT assay. &#x002A;P&#x003C;0.001 vs. control. The data were expressed as the mean &#x00B1; standard deviation of three replicate experiments.</p></caption>
<graphic xlink:href="ol-10-03-1416-g01.TIF"/>
</fig>
<fig id="f3-ol-0-0-3391" position="float">
<label>Figure 3.</label>
<caption><p>Cell apoptosis induced by guggulsterone. (A) Human cholangiocarcinoma cells were incubated in (a) medium alone for 72 h or (b) medium containing 60 &#x00B5;mol/l Z-guggulsterone for 72 h. The viable cells possessed normal-shaped nuclei that were faintly stained with Hoechst 33258. The apoptotic cells possessed shrunken nuclei with evidence of chromatin condensation. The results are representative of three replicate experiments (magnification, x200). (B) The human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells were incubated in the medium in the absence or presence of 60 &#x00B5;mol/l Z-guggulsterone for the indicated times. A characteristic DNA ladder was clearly observed subsequent to the treatment of the cells (M, 100 bp DNA marker). (C) Following treatment of the Sk-ChA-1 and Mz-ChA-1 cells with various concentrations of Z-guggulsterone for 24, 48 and 72 h, the apoptotic rate was detected. &#x002A;P&#x003C;0.001 vs. control. The data are expressed as the mean &#x00B1; standard deviation of three replicate experiments.</p></caption>
<graphic xlink:href="ol-10-03-1416-g02.jpg"/>
</fig>
<fig id="f4-ol-0-0-3391" position="float">
<label>Figure 4.</label>
<caption><p>Caspases involved in guggulsterone-induced apoptosis. (A) Effect of caspase inhibitors on guggulsterone-induced apoptosis. The Sk-ChA-1 and Mz-ChA-1 cells were cultured in the absence or presence of 100 &#x00B5;M z-VAD-fmk, z-LEHD-fmk or z-IETD-fmk for 2 h prior to the addition of 60 &#x00B5;mol/l Z-guggulsterone, and the cells were then incubated for 72 h. The data are expressed as the mean &#x00B1; SD of three replicate experiments. &#x002A;P&#x003C;0.01, &#x002A;&#x002A;P&#x003C;0.001 vs. Z-guggulsterone group. (B) Activity of caspase-3, -8 and -9 in guggulsterone-treated cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells. Subsequent to treatment with 60 &#x00B5;mol/l Z-guggulsterone for the indicated times, the cytosolic fraction of the cells was analyzed for changes in the activity of caspases-3, -8 and -9 using a colorimetric assay. The data are expressed as the mean &#x00B1; SD of three independent experiments. (C) Cleavage of PARP in guggulsterone treated cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cells. The cells were treated with 60 &#x00B5;mol/l Z-guggulsterone for the indicated times, and then whole-cell underwent western blotting to assess the expression of the 85 kDa cleaved PARP. &#x03B2;-actin was used as internal control to ensure that equal amounts of proteins were loaded into each lane. (a) The western blotting results are representative of three replicate experiments. (b) The densities of the cleaved PARP bands were determined and the relative quantity of the target protein was reported as RU. SD, standard deviation; PARP, poly (adenosine diphosphate-ribose) polymerase; RU, relative units.</p></caption>
<graphic xlink:href="ol-10-03-1416-g03.jpg"/>
</fig>
<fig id="f5-ol-0-0-3391" position="float">
<label>Figure 5.</label>
<caption><p>Effect of guggulsterone on the expression of apoptosis-associated genes. Subsequent to treatment with 60 &#x00B5;mol/l Z-guggulsterone for 24, 48 and 72 h, the whole-cell lysates were subjected to western blotting to assess the expression of the survivin, Bcl-2 and Bax proteins. &#x03B2;-actin was used as internal control to ensure that equal amounts of proteins were loaded into each lane. (A) The western blotting results are representative of three replicate experiments. (B) The densities of the protein bands was determined and the relative quantity of the target protein was reported as RU. Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; RU, relative units.</p></caption>
<graphic xlink:href="ol-10-03-1416-g04.jpg"/>
</fig>
</floats-group>
</article>
